Chlamydia Trachomatis Clinical Trial
Official title:
Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment
The purpose of this on-going study is to study the number of days after antibiotic treatment has commenced (due to infection caused by the sexually transmitted bacteria Chlamydia trachomatis (CT) and Mycoplasma genitalium(Mg)) it takes to be cured i.e to get a negative test result. The specimens are analyzed on first-catch-urine (men) or patient's self-obtained vaginal sample with quantitive nucleic acid amplification test(NAAT). A secondary aim is to detect macrolide resistant Mg-strains and study whether there are any emerging macrolide resistant Mg-strains after treatment with azithromycin. A third aim is to study whether the participating subjects are adherent to the study protocol meaning 12 samples taken during a period of four weeks.
Mycoplasma genitalium (Mg), detected in 1980, causes a urogenital infection through sexual
transmission. In contrast to Chlamydia trachomatis antibiotic resistance is common against
tetracyclines and is emerging against macrolides such as azithromycin. Both antibiotics are
recommended as the first line treatment of chlamydia infection. Recent published data,
however, indicate that 1g azithromycin stat may be only bacteriostatic when treating
chlamydia.
The consensus to date is that there should always be a test of cure in pregnant women having
been treated for chlamydia and in all individuals treated for Mg.
There are no studies published, to our knowledge, where the time to eradication after
antibiotic treatment commenced in Mg infection has been evaluated. The first line treatment
of a confirmed Mg infection is azithromycin 1.5 g given during a period of 5 days. If
macrolide resistance is plausible or confirmed moxifloxacin 400mg for 7 to 10 days is
recommended.
Individuals with symptomatic urethritis or cervicitis and/or being sexual partners to
individuals being treated for a suspect or confirmed Mg or CT infection were eligible. The
study subjects were patients attending either of the STD-clinics in Norrköping or Västervik,
Sweden. All samples were sent to Statens Serum Institut(SSI), Mycoplasma department (Jorgen
Skov Jensen) for analysis.
Patients accepting enrolment with a confirmed or highly suspected Mg were receiving
azithromycin 500 mg the first day and 250mg the following four days.
Patients where macrolide resistant Mg-strain infection was highly suspected received
moxifloxacin 400 mg once daily for seven days.
Those subjects intended to treatment but with a lower degree of suspicion of Mg infection
were randomized to either a treatment with doxycycline 200 mg the first day and 100 mg once
daily the following nine days (the custom and recommendation in Sweden for treatment of
chlamydia and non-specific urethritis or cervicitis) OR a treatment with azithromycin 1g as
a single dose.
All participants were given test kits for 12 samples, which were to be sampled three times
weekly (every second day) during four weeks starting the day after the first day of
treatment. They were instructed not to have any sexual intercourse during the first week and
with condom afterwards during the study period. The samples were to be sent once weekly
(three samples)to SSI.The date of sampling was to be noted on the label of the tube and the
attaching paper to SSI, where also any symptoms were to be noted. The results of the tests
were sent to the STD-clinic who informed the patient.
The study started in February 2010 and inclusion of patients have ended for those subjects
with a verified M genitalium infection (February 2014), whereas patients with a verified or
suspected chlamydia infection still are enrolled and randomised to azithromycin 1 g or
doxycycline. A manuscript will soon be submitted concerning those subjects being treated for
a M genitalium infection.
To date 190 patients have been enrolled and also fulfilled the study protocol with sampling
of specimens.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676816 -
Self Sampling for Rapid Turnaround Testing in the Emergency Department
|
N/A | |
Completed |
NCT00213018 -
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
|
Phase 2 | |
Completed |
NCT00827970 -
Randomized Population-Based Study on Chlamydia Trachomatis Screening
|
N/A | |
Withdrawn |
NCT01358799 -
Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System
|
N/A | |
Completed |
NCT01733069 -
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
|
N/A | |
Completed |
NCT00978848 -
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
|
N/A | |
Completed |
NCT02391233 -
Multimedia WORTH With Black Drug-Involved Women on Probation
|
N/A | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT03071510 -
Evaluation of the Atlas Genetics io® CTNG System
|
||
Recruiting |
NCT04446611 -
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes
|
N/A | |
Completed |
NCT01329588 -
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
|
Phase 4 | |
Not yet recruiting |
NCT06216964 -
Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study
|
N/A | |
Terminated |
NCT02795975 -
Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples
|
N/A | |
Completed |
NCT00213057 -
Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand
|
Phase 1 | |
Completed |
NCT00207454 -
Optimizing Strategies to Improve STD Partner Services
|
Phase 1 | |
Completed |
NCT00177437 -
Home Screening for Chlamydia Surveillance
|
Phase 3 | |
Completed |
NCT02787109 -
Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years
|
Phase 1 | |
Completed |
NCT01665690 -
Washington State Community Expedited Partner Treatment (EPT) Trial
|
Phase 4 | |
Completed |
NCT02128620 -
A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 |